Reality of the emetogenic level of irinotecan
Garcia-Del-Barrio MA (1), Martin-Algarra S (2), Aldaz Pastor A (3).
(1) Pharmacy Department, Clínica Universidad de Navarra, Pamplona, Spain.
(2) Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(3) Pharmacy Department, Clínica Universidad de Navarra, Pamplona, Spain.
To assess the emetogenic potential of different chemotherapy (CT) regimens in daily clinical practice in an outpatient setting. To optimize antiemetic prophylaxis if necessary
Prospective and retrospective review of the emetogenic potential of CT regimens used in adult patients in an outpatient setting
We assess the chemotherapy-induced nausea and vomiting (CINV) of 50 different CT regimens used on 157 different patients in an outpatient setting.
We found that the CT usually classified as highly emetogenic, including cisplatin and anthracycline-cyclophosphamide combination, had the higher incidence of CINV (37.5 and 54.4% respectively).
The antineoplastic drugs usually considered to be moderately emetogenic had, as expected, lower rates of emesis with the exception of irinotecan, which presented a pattern of nausea and/or vomiting (NV) similar to the highly emetogenic CT with a global incidence of 48.5%. The appearance of emetic symptoms had impact on quality of life in 70% of the patients, with nausea being the main emetic symptom.
Antiemetic prophylaxis for highly emetogenic CT could be improve. Irinotecan CT regimens have a high emetogenic potential more than moderate and require more intensive antiemetic prophylaxis too.
CITA DEL ARTÍCULO Support Care Cancer. 2018 Apr 21. doi: 10.1007/s00520-018-4196-z.